PATENT CLAIM ANALYSIS

Application Number: 15967452
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2019-04
Patent Classification: ["514", "254070"]

Abstract:
Described herein are methods of treating non-metastatic castrate-resistant prostate cancer using an approved drug product comprising apalutamide, enzalutamide or darolutamide. Also described here are drug products containing apalutamide enzalutamide or darolutamide, and methods of selling or offering for sale an anti-androgen drug product.

Claim (Index 36):
A method of improving metastasis free survival in a male human with non-metastatic castration-resistant prostate cancer, said method comprising providing to said male human an approved drug product comprising apalutamide in combination with androgen deprivation therapy.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 91.0
- Lexical Diversity: 1.42424
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15967442', '15851444', '14523333', '15222734', '14380606']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7400183348214184
- 35 USC 102 Novelty (BERT): 0.536096594082834
- Combined Prediction Score: 0.71962616074756
- Mean Citation Score: 336.3110680000001
- Max Citation Score: 358.95117
- Similarity Product: 292.691481382463

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test